By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Genome British Columbia and Genome Canada today announced nearly C$4.3million (US$4.3 million) in funding for the development of genomic diagnostics aimed at forest disease.
In a paper published this week in PNAS, a University of British Columbia team led by Fluidigm SAB member Carl Hansen described a fully integrated microfluidic device for performing reverse transcription quantitative PCR and measuring single-cell gene expression in hundreds of cells in parallel.
The technology could improve the utility of digital PCR in diagnostic applications, and help drive the technique's adoption as a low-cost alternative to quantitative real-time PCR for applications such as copy number variation, rare allele detection, and single-cell gene expression analysis.
Under the terms of the research alliance, which was forged in 2009, Alnylam has the exclusive rights to all new inventions in the RNAi field, as well as rights to sublicense any resulting intellectual property to Alnylam's current and future partners.